Expected consequences of moving US pharma manufacturing to the US, by gender

This statistic shows the results of a survey conducted in the United States in February 2017, by gender. U.S. adults were given a list of 11 options and asked to select which consequences they would expect if U.S. pharma companies were forced to move their manufacturing from abroad back to the U.S. About 42 percent of female respondents said that they would expect higher drug prices, while 41 percent of male respondents indicated the same.